OpenURL Connection Search

Select item for more details and to access through your institution.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Published in:
2020
By:
- Kim, Stefano;
- Buecher, Bruno;
- André, Thierry;
- Jary, Marine;
- Bidard, François-Clément;
- Ghiringhelli, François;
- François, Éric;
- Taieb, Julien;
- Smith, Denis;
- de la Fouchardière, Christelle;
- Desramé, Jérôme;
- Samalin, Emmanuelle;
- Parzy, Aurélie;
- Baba-Hamed, Nabil;
- Bouché, Olivier;
- Tougeron, David;
- Dahan, Laëtitia;
- El Hajbi, Farid;
- Jacquin, Marion;
- Rebucci-Peixoto, Magali
Publication type:
journal article
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82).
Published in:
BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11065-0
By:
- Vienot, Angélique;
- Jacquin, Marion;
- Rebucci-Peixoto, Magali;
- Pureur, Dimitri;
- Ghiringhelli, François;
- Assenat, Eric;
- Hammel, Pascal;
- Rosmorduc, Olivier;
- Stouvenot, Morgane;
- Allaire, Manon;
- Bouattour, Mohamed;
- Regnault, Hélène;
- Fratte, Serge;
- Raymond, Eric;
- Soularue, Emilie;
- Husson-Wetzel, Stéphanie;
- Di Martino, Vincent;
- Muller, Allison;
- Clairet, Anne-Laure;
- Fagnoni-Legat, Christine
Publication type:
Article
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.918499
By:
- Kim, Stefano;
- Boustani, Jihane;
- Vernerey, Dewi;
- Vendrely, Vèronique;
- Evesque, Ludovic;
- Francois, Eric;
- Quero, Laurent;
- Ghiringhelli, Francois;
- de la Fouchardière, Christelle;
- Dahan, Laëtitia;
- Bouche´, Oliver;
- Chibaudel, Benoist;
- Hajbi, Farid El;
- Vernet, Chloè;
- Rebucci-Peixoto, Magali;
- Feuersinger, Alexandra;
- Maritaz, Christophe;
- Borg, Christophe
Publication type:
Article
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.957580
By:
- Rebucci-Peixoto, Magali;
- Vienot, Angélique;
- Adotevi, Olivier;
- Jacquin, Marion;
- Ghiringhelli, Francois;
- de la Fouchardière, Christelle;
- You, Benoit;
- Maurina, Tristan;
- Kalbacher, Elsa;
- Bazan, Fernando;
- Meynard, Guillaume;
- Clairet, Anne-Laure;
- Fagnoni-Legat, Christine;
- Spehner, Laurie;
- Bouard, Adeline;
- Vernerey, Dewi;
- Meurisse, Aurélia;
- Kim, Stefano;
- Borg, Christophe;
- Mansi, Laura
Publication type:
Article

Found: 4

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82).

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.